Josep Martí

Josep Martí

Auto-generated profile, based on publicly available information

Josep Martí

Liver Surgery & Transplantation Unit, Department of Surgery, ICMDM, Hospital Clinic, IDIBAPS, CIBERehd, Villarroel, 170, 08036, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
GSGonzalo Sapisochin
Gonzalo Sapisochin
MFM. Facciuto
M. Facciuto
LRL. Rubbia‐Brandt
L. Rubbia‐Brandt
JMJ. Marti
J. Marti
NMN. Mehta
N. Mehta
OCon behalf of the iCCA International Consortium
on behalf of the iCCA International Consortium
The presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is a contraindication for liver transplantation in most centers worldwide. Recent investigations have shown that “very early” iCCA (single tumors ≤2 cm) may have acceptable results after liver transplantation. This study further evaluates this finding in a larger international multicenter cohort. The study group was composed of those patients who were transplanted for hepatocellular carcinoma or decompensated cirrhosis and found to have an iCCA at explant pathology. Patients were divided into those with “very early” iCCA and those with “advanced” disease (single tumor >2 cm or multifocal disease). Between January 2000 and December 2013, 81 patients were found to have an iCCA at explant; 33 had separate nodules of iCCA and hepatocellular carcinoma, and 48 had only iCCA (study group). Within the study group, 15/48 (31%) constituted the “very early” iCCA group and 33/48 (69%) the “advanced” group. There were no significant differences between groups in preoperative characteristics. At explant, the median size of the largest tumor was larger in the “advanced” group (3.1 [2.5‐4.4] versus 1.6 [1.5‐1.8]). After a median follow‐up of 35 (13.5‐76.4) months, the 1‐year, 3‐year, and 5‐year cumulative risks of recurrence were, respectively, 7%, 18%, and 18% in the very early iCCA group versus 30%, 47%, and 61% in the advanced iCCA group, P = 0.01. The 1‐year, 3‐year, and 5‐year actuarial survival rates were, respectively, 93%, 84%, and 65% in the very early iCCA group versus 79%, 50%, and 45% in the advanced iCCA group, P = 0.02. Conclusion: Patients with cirrhosis and very early iCCA may become candidates for liver transplantation; a prospective multicenter clinical trial is needed to further confirm these results. (Hepatology 2016;64:1178‐1188)

1 September 2007 in American Journal of Transplantation
Verified
Journal Article
Open access
AAA. Amador
A. Amador
LGL. Grande
L. Grande
JMJ. Martí
J. Martí
RDR. Deulofeu
R. Deulofeu
RMR. Miquel
R. Miquel
JGJ.C García-Valdecasas
J.C García-Valdecasas
To assess the immediate and long-term effects of ischemic preconditioning (IPC) in deceased donor. liver transplantation (LT), we designed a prospective, randomized controlled trial involving 60 donors: control group (CTL, n = 30) or study group (IPC, n = 30). IPC was induced by 10-min hiliar clamping immediately before recovery of organs. Clinical data and blood and liver samples were obtained in the donor and in the recipient for measurements. IPC significantly improved biochemical markers of liver cell function such as uric acid, hyaluronic acid and Hypoxia-Induced Factor-1 alpha (HIF-1 alpha) levels. Moreover, the degree of apoptosis was significantly lower in the IPC group. On clinical basis, IPC significantly improved the serum aspartate aminotransferase (AST) levels and reduced the need for reoperation in the postoperative period. Moreover, the incidence of primary nonfunction (PNF) was lower in the IPC group, but did not achieve statistical significance. We conclude that 10-min IPC protects against I/R injury in deceased donor LT.

1 September 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DGDavide Ghinolfi
Davide Ghinolfi
JMJ. Marti
J. Marti
PSP. De Simone
P. De Simone
QLQuirino Lai
Quirino Lai
DPD. Pezzati
D. Pezzati
FFF. Filipponi
F. Filipponi
Use of very old donors in liver transplantation (LT) is controversial because advanced donor age is associated with a higher risk for graft dysfunction and worse long-term results, especially for hepatitis C virus (HCV)-positive recipients. This was a retrospective, single-center review of primary, ABO-compatible LT performed between 2001 and 2010. Recipients were stratified in four groups based on donor age (<60 years; 60-69 years; 70-79 years and ≥80 years) and their outcomes were compared. A total of 842 patients were included: 348 (41.3%) with donors <60 years; 176 (20.9%) with donors 60-69 years; 233 (27.7%) with donors 70-79 years and 85 (10.1%) with donors ≥80 years. There was no difference across groups in terms of early (≤30 days) graft loss, and graft survival at 1 and 5 years was 90.5% and 78.6% for grafts <60 years; 88.6% and 81.3% for grafts 60-69 years; 87.6% and 75.1% for grafts 70-79 years and 84.7% and 77.1% for grafts ≥80 years (p = 0.065). In the group ≥80 years, the 5-year graft survival was lower for HCV-positive versus HCV-negative recipients (62.4% vs. 85.6%, p = 0.034). Based on our experience, grafts from donors ≥80 years may provide favorable results but require appropriate selection and allocation policies.

1 October 2014 in Annals of Surgery
Verified
Journal Article
Closed access
BFBernardo Franssen
Bernardo Franssen
KAKutaiba Alshebeeb
Kutaiba Alshebeeb
PTParissa Tabrizian
Parissa Tabrizian
JMJosep Marti
Josep Marti
EPElisa Sefora Pierobon
Elisa Sefora Pierobon
MSMyron E. Schwartz
Myron E. Schwartz
Compare surgical outcomes for hepatitis B virus (HBV)-hepatocellular carcinoma (HCC) versus hepatitis C virus (HCV)-hepatocellular carcinoma (HCC). HCC is the second leading cause of death from cancer worldwide and is associated with hepatitis virus infection in 80% of cases. Between 1997 and 2011, 1008 patients with hepatitis B (HBV, n = 431) or hepatitis C (HCV, n = 577) underwent resection (n = 567) or transplantation (n = 441). Resection was indicated for Child's A patients with single HCC; transplantation was indicated for patients within Milan criteria. Univariate and multivariate analyses were performed as well as survival and recurrence analysis using log-rank test. Based on uniform application of these criteria, resection: transplantation ratio was 3.6 for patients with HBV and 0.67 for patients with HCV. Resection: Patients with HBV had larger tumors and higher α-fetoprotein but less satellites and macrovascular invasion; 68% of HBV versus 89% of HCV were cirrhotic. Survival was better (P < 0.001) and recurrence was lower (P = 0.009) for HBV. Independent predictors of death included HCV (P = 0.024), transfusion (P = 0.013), and HCC of greater than 5 cm (P = 0.013). Limiting analysis to patients with cirrhosis, survival with HBV remained superior (P = 0.020) but recurrence did not. Transplantation: Tumors were similar in HBV and HCV. Survival was better (P = 0.002) for HBV; recurrence was similar. Independent predictors of death were HCV (P < 0.001), poor differentiation (P = 0.049), vascular invasion (P = 0.002), and outside Milan (P = 0.032). Limiting analysis to patients within Milan, HBV survival remained better for both resection (P = 0.030) and transplantation (P = 0.002). Survival after both resection and transplantation for HCC was better in HBV- than in HCV-related HCC whereas recurrence was also lower for HBV-HCC in the resection group, these differences are influenced by both liver and tumor factors.

3 February 2017 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
DDDelia D'AVola
Delia D'AVola
VCValentín Cuervas‐Mons
Valentín Cuervas‐Mons
JMJosep Martí
Josep Martí
JUJorge Ortiz de Urbina
Jorge Ortiz de Urbina
LLLaura Lladó
Laura Lladó
JHJosé Ignacio Herrero
José Ignacio Herrero

19 August 2009 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
ÓVÓscar Vidal
Óscar Vidal
MVMauro Valentini
Mauro Valentini
CGCesar Ginestà
Cesar Ginestà
JMJosep Martí
Josep Martí
JEJuan J. Espert
Juan J. Espert
JGJuan C. García-Valdecasas
Juan C. García-Valdecasas